Atea Pharmaceuticals

AVIR50

Penny Stock

$3.31arrow_drop_down1.04%-$0.03

Penny Stock

AVIR50

$3.31

arrow_drop_down1.04%-$0.03

Penny Stock

Performance History

Key Stats
Open	$3.38
Prev. Close	$3.36
EPS	-2.10
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$281.26M
PE Ratio	-

	LOW	HIGH
Day Range	3.32	3.43
52 Week Range	2.76	4.60

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-2.10

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Atea Pharmaceuticals (AVIR)

Atea Pharmaceuticals Inc (AVIR) is a biopharmaceutical company that focuses on developing and commercializing novel antiviral therapeutics for the treatment of life-threatening viral infections. The company's lead product candidate, AT-527, is an orally administered, direct-acting antiviral agent that inhibits the replication of RNA viruses, including coronaviruses. AT-527 has shown promising results in preclinical and clinical studies, demonstrating potent antiviral activity against various viruses, including SARS-CoV-2, the virus responsible for COVID-19.

Atea Pharmaceuticals Inc has a market capitalization of $X billion. The stock price of AVIR has experienced significant volatility in the past year, with a 52-week range of $X to $X. As of today, the stock is trading within a day range of $X to $X. The trading volume of AVIR has been relatively high, indicating investor interest in the company.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Jean-Pierre Sommadossi Ph.D.
Headquarters: Boston
Employees: 72
Exchange: NASDAQ

Keep an eye on Atea Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Atea Pharmaceuticals 's (AVIR) price per share?

The current price per share for Atea Pharmaceuticals (AVIR) is $3.31. The stock has seen a price change of -$0.04 recently, indicating a -1.04% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Atea Pharmaceuticals (AVIR)?

For Atea Pharmaceuticals (AVIR), the 52-week high is $4.6, which is 38.97% from the current price. The 52-week low is $2.76, the current price is 19.71% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Atea Pharmaceuticals (AVIR) a growth stock?

Atea Pharmaceuticals (AVIR) has shown an average price growth of -3.55% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Atea Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Atea Pharmaceuticals (AVIR) stock price performance year to date (YTD)?

As of the latest data, Atea Pharmaceuticals (AVIR) has a year-to-date price change of 3.12%. Over the past month, the stock has experienced a price change of -6.23%. Over the last three months, the change has been -8.06%. Over the past six months, the figure is -16.41%.

help

Is Atea Pharmaceuticals (AVIR) a profitable company?

Atea Pharmaceuticals (AVIR) has a net income of -$135.96M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$164.16M. Furthermore, the EBITDA is -$124.88M.

help

What is the market capitalization of Atea Pharmaceuticals (AVIR)?

Atea Pharmaceuticals (AVIR) has a market capitalization of $279.57M. The average daily trading volume is 3.33, indicating the stock's liquidity and investor engagement.

News

ZIMMER BIOMET HOLDINGS

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

CALENDAR OF EVENTS

May 29, 2024

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

CALENDAR OF EVENTS

CLINICAL STUDY

May 22, 2024

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

CALENDAR OF EVENTS

HEALTH

Apr 29, 2024

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

CLINICAL STUDY

Mar 27, 2024

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

EARNINGS RELEASES AND OPERATING RESULTS

Feb 28, 2024

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About Atea Pharmaceuticals (AVIR)

Keep an eye on Atea Pharmaceuticals

Frequently Asked Questions

What is Atea Pharmaceuticals 's (AVIR) price per share?

What is the 52-week high and low for Atea Pharmaceuticals (AVIR)?

Is Atea Pharmaceuticals (AVIR) a growth stock?

What is Atea Pharmaceuticals (AVIR) stock price performance year to date (YTD)?

Is Atea Pharmaceuticals (AVIR) a profitable company?

What is the market capitalization of Atea Pharmaceuticals (AVIR)?

News

Sign up for our newsletter

Take Your Investments to a Whole New Level